HAEMATO AG

HAEMATO AG: Termination of listing in the Open Market

HAEMATO AG publishes figures for the third quarter of 2023: Sales increase of around 13% compared to the same period of the previous year, strong increase in EBIT margin and significant increase in

Termination of the botulinum toxin project

HAEMATO AG publishes figures for the first half of 2023

HAEMATO AG with a strong start into the year 2023:   Revenue increase of over 25% compared to the same quarter of the previous year and disproportionate increase in the operating result

HAEMATO AG: Dividend of EUR 1.20

HAEMATO AG publishes preliminary figures for the 2022 financial year: Strong increase in net profit and operating cash flow

HAEMATO AG: publishes figures for the 3rd quarter 2022

HAEMATO AG publishes figures for Q2 2022: increase in revenues and EBIT compared to the previous quarter; confirmation of guidance for the full year 2022

HAEMATO AG publishes figures for Q1 2022: further improvement in EBIT margin and confirmation of guidance

HAEMATO AG: Dividend of EUR 1.10

HAEMATO AG – preliminary figures for the 2021 financial year: Renewed increase in sales and strong rise in earnings after disproportionate growth of the new Lifestyle and Aesthetics business unit

Expansion of the Executive Board of HAEMATO AG: Strengthening operational excellence

HAEMATO adds a new generation test device to its portfolio

HAEMATO distributes PCR point-of-care devices for effective containment of corona pandemic

HAEMATO AG reports figures for the 3rd quarter of 2021: Further increase in revenue and earnings as well as confirmation of revenue and earnings expectations for 2021

HAEMATO: HAEMATO seeks marketing authorization and plans distribution of a botulinum toxin product under its own brand in Europe

HAEMATO seeks marketing authorization and plans distribution of a botulinum toxin product under its own brand in Europe

HAEMATO AG announces preliminary figures for Q2 2021: Increase in Q2 revenue by 41% and EBIT by 596% compared to the same quarter last year.

HAEMATO AG with strong start to the year: EBIT rises in Q1 by 350 % to EUR 2.4 million and revenues by 22 % to EUR 73.9 million.

HAEMATO AG proposes dividend payment

According to the preliminary IFRS financial statements for the 2020 financial year, HAEMATO AG increased its revenue by 20.5 % to EUR 238.3 million and increased EBITDA by 74.8 % to EUR 3.3 million

HAEMATO AG successfully completes capital increase

HAEMATO AG plans cash capital increase to finance private label business

HAEMATO AG: HAEMATO PHARM GmbH as a subsidiary of HAEMATO AG receives a special approval according to § 11 Abs. 1 MPG

HAEMATO AG: Patrick Brenske to be the sole member of the Executive Board of HAEMATO AG in the future

HAEMATO AG: HAEMATO AG acquires ‘M1 Aesthetics GmbH’ from M1 Kliniken AG – Contribution of the company within the scope of a capital increase in kind of HAEMATO AG

HAEMATO AG: HAEMATO AG acquires ‘M1 Aesthetics GmbH’ from M1 Kliniken AG – Contribution of the company within the scope of a capital increase in kind of HAEMATO AG

HAEMATO AG: Expansion of the board of directors: Strengthening the strategic and operative implementa-tion of the product business in the Haemato Group

HAEMATO AG: The sales of HAEMATO AG increased in the first nine months of 2020 by 23.8 % compared to the same period of the previous year to 175.6 million EUR